Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masato Karayama

Showing results (181-190 of 194) with videos related to

Pageof 20
Sort By:
Cancer Immunology, Immunotherapy : CII|June 6, 2021
Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancerMasato Karayama, Naoki Inui, Yusuke Inoue, et al.
JAMA Network Open|September 21, 2020
Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung CancerYusuke Inoue, Katsuhiro Yoshimura, Koji Nishimoto, et al.
Scientific Reports|January 23, 2026
Serum interferon-λ3 as a short-term biomarker of disease control in anti-MDA5-positive dermatomyositis-associated ILDYoshihiro Kitahara, Tomoyuki Fujisawa, Atsuki Fukada, et al.
Respiratory Investigation|February 1, 2025
Prevalence and clinical features of progressive pulmonary fibrosis in patients with unclassifiable idiopathic interstitial pneumonia: A post hoc analysis of prospective multicenter registryMasato Kono, Noriyuki Enomoto, Yusuke Inoue, et al.
Respiratory Investigation|December 18, 2024
Association between the HAL score and the development of progressive pulmonary fibrosis in idiopathic interstitial pneumonia: A prospective observational studyHiromasa Nakayasu, Masato Karayama, Noriyuki Enomoto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2024
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III TrialNaoki Inui, Takahito Suzuki, Kazuki Tanaka, et al.
Scientific Reports|April 1, 2026
Geriatric nutritional risk index in antifibrotic therapy can predict tolerability and mortality riskTakuya Masuda, Yasutaka Mochizuka, Yuzo Suzuki, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 26, 2023
Prognostic Role of Interferon-λ3 in Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis-Associated Interstitial Lung DiseaseAtsuki Fukada, Tomoyuki Fujisawa, Hironao Hozumi, et al.
Respiratory Research|September 28, 2024
CXCL10 predicts autoimmune features and a favorable clinical course in patients with IIP: post hoc analysis of a prospective and multicenter cohort studyNoriyuki Enomoto, Shogo Nakai, Shusuke Yazawa, et al.
Scientific Reports|July 19, 2025
Analysis of the relationship between bronchoalveolar lavage lymphocyte fraction and detailed autoimmune features in patients with idiopathic interstitial pneumoniaNoriyuki Enomoto, Masayuki Watanuki, Shogo Nakai, et al.
Pageof 20

Showing results (181-190 of 194) with videos related to

Sort By:
Pageof 20
Cancer Immunology, Immunotherapy : CII|June 6, 2021
Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancerMasato Karayama, Naoki Inui, Yusuke Inoue, et al.
JAMA Network Open|September 21, 2020
Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung CancerYusuke Inoue, Katsuhiro Yoshimura, Koji Nishimoto, et al.
Scientific Reports|January 23, 2026
Serum interferon-λ3 as a short-term biomarker of disease control in anti-MDA5-positive dermatomyositis-associated ILDYoshihiro Kitahara, Tomoyuki Fujisawa, Atsuki Fukada, et al.
Respiratory Investigation|February 1, 2025
Prevalence and clinical features of progressive pulmonary fibrosis in patients with unclassifiable idiopathic interstitial pneumonia: A post hoc analysis of prospective multicenter registryMasato Kono, Noriyuki Enomoto, Yusuke Inoue, et al.
Respiratory Investigation|December 18, 2024
Association between the HAL score and the development of progressive pulmonary fibrosis in idiopathic interstitial pneumonia: A prospective observational studyHiromasa Nakayasu, Masato Karayama, Noriyuki Enomoto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2024
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III TrialNaoki Inui, Takahito Suzuki, Kazuki Tanaka, et al.
Scientific Reports|April 1, 2026
Geriatric nutritional risk index in antifibrotic therapy can predict tolerability and mortality riskTakuya Masuda, Yasutaka Mochizuka, Yuzo Suzuki, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 26, 2023
Prognostic Role of Interferon-λ3 in Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis-Associated Interstitial Lung DiseaseAtsuki Fukada, Tomoyuki Fujisawa, Hironao Hozumi, et al.
Respiratory Research|September 28, 2024
CXCL10 predicts autoimmune features and a favorable clinical course in patients with IIP: post hoc analysis of a prospective and multicenter cohort studyNoriyuki Enomoto, Shogo Nakai, Shusuke Yazawa, et al.
Scientific Reports|July 19, 2025
Analysis of the relationship between bronchoalveolar lavage lymphocyte fraction and detailed autoimmune features in patients with idiopathic interstitial pneumoniaNoriyuki Enomoto, Masayuki Watanuki, Shogo Nakai, et al.
Pageof 20